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the surgical treatment.
Results: Tumour response (pCR, pPR) of more than 70 % can be
achieved using neoadjuvant TEC-regimen. The preliminary
expression profiling results shown here indicate a subset of 148
genes that classifies all patients with a complete remission
(pCR). A comparable separation of the groups could not achieved
by established tumor factors, e.g. ER, PgR, HER2, uPA, which are
measured simultaneously on the HGSM and also statistically
evaluated.
Conclusions: HGSM semi-quantitative expression profiling is
promising to have the potential to figure out genes that are
related to cancer progression and chemotherapy resistance, espe-
cially in primary systemic chemotherapy.
doi:10.1016/j.ejcsup.2006.04.122
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Background: Pancreatic cancer is the tumor with the highest risk
for thromboembolic complications. Tissue factor represents the
principal initiator of coagulation. The aim of this study is to study
expression of tissue factor (TF) in pancreatic cancer.
Methods: TF expression was studied in human pancreatic carci-
noma cell lines by Northern blot and immunofluorescence.
Expression of alternatively spliced TF (asTF) was assessed by
RT-PCR. TF expression was determined by immunofluorescence
in tissues of pancreatic adenocarcinoma (PCa), chronic pancreati-
tis (CP) and normal controls. Plasma samples (30 PCa-patients, 13
CP-patients and 20 controls) were investigated for soluble TF lev-
els and coagulation activation markers (thrombin-antithrombin
III complex [TAT], prothrombin fragment 1 + 2 (F1 + 2)).
Results: All pancreatic carcinoma cell lines expressed TF (8/8)
and most of them asTF (6/8). All but two pancreatic cancer tissue
samples stained positive for TF (17/19). In all samples of cP weak
staining was restricted to pancreatic duct cells. TF and TAT levels
in PCa patients were significantly elevated whereas elevated
F1 + 2 levels did not reach statistical significance compared to
controls. In CP patients TAT and F1 + 2 levels proved to be signif-
icantly elevated compared to controls, although TAT elevation
was less pronounced than in PCa patients.
Conclusion: We conclude that in addition to the upregulated
expression of TF on the cell membrane soluble TF might be piv-
otal for activation of coagulation in pancreatic cancer.
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Background: Pancreatic carcinoma is particularly aggressive
tumor, it has a poor prognosis and at the time of diagnosis,
the tumor is generally in an advanced stage no longer suitable
for resection. Moreover, this tumor is virtually resistant to con-
ventional radio-/chemotherapy. Thus alternative therapy
modalities are urgently needed. Morphologically pancreatic
adenocarcinoma is characterized by a dense stromal reaction
comprised of activated pancreatic stellate cells. This stroma
may protect the tumor cells against the patients immune sys-
tem and may in part be responsible for the chemoresistance
of the tumor cells. Polysaccharide-K (polysaccharide-Kureha;
PSK), also known as krestin, is a unique protein-bound polysac-
charide derived from the CM-101 strain of the fungus Coriolus
versicolor, which has been used successfully as a chemoimmu-
notherapy agent in the treatment of various cancers in Asia for
over 30 years, however there is only one publication concerning
the combined treatment of two pancreatic cancer patients with
Cisplatin, PSK and UFT. PSK not only boosts the immune sys-
tem of patients but also has direct antineoplastic effects. So
it has been shown, that PSK reduces the invasiveness of a
pancreatic tumor cell line by downregulating TGFbeta1 and
MMP.
Aim and Methods: In order to analyze, if the reduction of the
invasive potential by PSK is a general phenomenon in pancreatic
tumor cells, we treated a panel of different pancreatic tumor cell
lines with PSK and subsequently analyzed changes in gene
expression using RT-PCR. Moreover, the activity of MMPs was ana-
lyzed using zymography, proliferation of the cells after PSK treat-
ment was analyzed by WST-1 assay.
Results: Treatment of the pancreatic tumor cells with PSK for
up to six days resulted in a short term induction of the cell
cycle inhibitor p21/WAF1 at 4 and 24 h, after that expression
returned to basal levels. In contrast PCNA and cycD1 expression
gradually decreased during the PSK treatment, reaching maxi-
mal repression after about three days, which persisted for the
rest of the treatment period. In contrast to the published results
PSK did not change MMP expression, neither on the RNA level
analyzed by RT-PCR nor on the protein level as analyzed by
zymography. Moreover, PSK dose dependently decreased the
proliferation of all pancreatic tumor cells investigated, reaching
a plateau of about 40% decrease of proliferation at a concentra-
tion of 250 lg/ml PSK. A further increase of PSK concentration
had only marginal additional effects on the proliferation of
the cells.
Conclusion: Our results demonstrate a direct antineoplastic
effect of PSK on pancreatic tumor cells by decreasing the prolifer-
ation of the cells, pointing on the possibility for the use of PSK in
the treatment of pancreatic cancer.
doi:10.1016/j.ejcsup.2006.04.124
